STOCK TITAN
  1. Home
  2. Financials
  3. INTI

Inhibitor Therap Financials

INTI
Source SEC Filings (10-K/10-Q) Data as of Mar 31, 2026 Currency USD FYE December

This page shows Inhibitor Therap (INTI) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 14 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI INTI FY2025

Recurring cash burn is shrinking the asset base faster than costs are falling, leaving a liquid but undercapitalized company.

FY2025 shows the key split: short-term liquidity still looks workable, with a current ratio of 3.2x and cash of $2.4M. But negative equity of about -$1.3M shows that repeated losses have already exhausted the capital cushion, creating a clear gap between bill-paying capacity and long-term balance-sheet support.

The operating model has been remarkably steady in the wrong direction: operating cash outflow stayed near -$3.2M even as SG&A eased to $1.7M. That suggests the business has not yet found a lower-burn base, and spending is still split between development work and corporate overhead rather than concentrated in one easily reduced bucket.

Loss absorption, not heavy dilution, appears to be the main balance-sheet driver: equity went from $8.3M positive to -$1.3M negative while the share count was roughly flat. Because the earlier jump in cash and reported profit did not persist, the company ultimately consumed that cushion instead of turning it into a self-funding operating engine.

Generated by Rhea from SEC filings [ NOT FINANCIAL ADVICE ]

Financial Health Signals

Financial health score pending refresh

We are recalculating Inhibitor Therap's peer-relative financial health score against the latest fiscal year. It will appear here once the refresh completes. The signals and metrics below are current.

Piotroski F-Score Partial
1/6

Inhibitor Therap passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality Low Quality
0.98x

For every $1 of reported earnings, Inhibitor Therap generates $0.98 in operating cash flow (-$3.2M OCF vs -$3.3M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
N/A
EBITDA
N/A
Net Income
-$3.3M
YoY+1.2%

Inhibitor Therap reported -$3.3M in net income in fiscal year 2025. This represents an increase of 1.2% from the prior year.

EPS (Diluted)
$-0.02
YoY+0.0%

Inhibitor Therap earned $-0.02 per diluted share (EPS) in fiscal year 2025. This represents an increase of 0.0% from the prior year.

Cash & Balance Sheet

Free Cash Flow
N/A
Cash & Debt
$2.4M
YoY-57.6%
5Y CAGR+99.6%
10Y CAGR+14.7%

Inhibitor Therap held $2.4M in cash against $37K in long-term debt as of fiscal year 2025.

Dividends Per Share
N/A
Shares Outstanding
173M
YoY+0.1%
5Y CAGR-14.3%
10Y CAGR-3.5%

Inhibitor Therap had 173M shares outstanding in fiscal year 2025. This represents an increase of 0.1% from the prior year.

Margins & Returns

Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
Return on Equity
N/A

Capital Allocation

R&D Spending
$1.7M
YoY-3.5%
5Y CAGR+55.7%
10Y CAGR+0.1%

Inhibitor Therap invested $1.7M in research and development in fiscal year 2025. This represents a decrease of 3.5% from the prior year.

Share Buybacks
N/A
Capital Expenditures
N/A

INTI Income Statement

Metric Q1'26 Q4'25 Q3'25 Q2'25 Q1'25 Q4'24 Q3'24 Q2'24
Revenue N/A N/A N/A N/A N/A N/A N/A N/A
Cost of Revenue N/A N/A N/A N/A N/A N/A N/A N/A
Gross Profit N/A N/A N/A N/A N/A N/A N/A N/A
R&D Expenses $341K N/A $378K+16.0% $326K+37.9% $236K N/A $370K+54.2% $240K
SG&A Expenses $355K N/A $363K-1.8% $370K-15.6% $438K N/A $444K+28.4% $345K
Operating Income -$696K N/A -$741K-6.5% -$696K-3.1% -$675K N/A -$813K-39.0% -$585K
Interest Expense N/A N/A N/A N/A N/A N/A N/A N/A
Income Tax N/A N/A N/A N/A N/A N/A N/A N/A
Net Income -$686K N/A -$712K-7.9% -$660K-4.3% -$633K N/A -$731K-45.7% -$502K
EPS (Diluted) $0.00 N/A $0.00 $0.00 $0.00 N/A $0.00 $0.00

INTI Balance Sheet

Metric Q1'26 Q4'25 Q3'25 Q2'25 Q1'25 Q4'24 Q3'24 Q2'24
Total Assets $1.4M-42.9% $2.5M-19.9% $3.1M-19.8% $3.9M-13.3% $4.5M-20.9% $5.7M-11.7% $6.5M-10.1% $7.2M
Current Assets $1.4M-43.8% $2.4M-20.1% $3.1M-20.0% $3.8M-13.4% $4.4M-22.4% $5.7M-11.7% $6.5M-10.1% $7.2M
Cash & Equivalents $1.3M-45.7% $2.4M-20.2% $3.0M-20.4% $3.7M-13.5% $4.3M-22.9% $5.6M-12.1% $6.4M-10.1% $7.1M
Inventory N/A N/A N/A N/A N/A N/A N/A N/A
Accounts Receivable N/A N/A N/A N/A N/A N/A N/A N/A
Goodwill N/A N/A N/A N/A N/A N/A N/A N/A
Total Liabilities $3.4M-10.3% $3.8M+21.4% $3.1M-1.9% $3.2M+1.2% $3.2M-15.0% $3.7M+21.8% $3.0M+0.3% $3.0M
Current Liabilities $382K-50.1% $766K+775.5% $88K-37.5% $140K+47.8% $95K-86.7% $710K+1492.5% $45K+25.4% $36K
Long-Term Debt $29K-20.4% $37K-16.5% $44K-15.1% $52K-10.8% $58K N/A N/A N/A
Total Equity -$2.0M-53.1% -$1.3M-37514.2% $3K-99.5% $716K-47.1% $1.4M-31.9% $2.0M-41.7% $3.4M-17.7% $4.1M
Retained Earnings -$56.1M-1.2% -$55.4M-2.4% -$54.1M-1.3% -$53.4M-1.3% -$52.8M-1.2% -$52.1M-2.8% -$50.7M-1.5% -$50.0M

INTI Cash Flow Statement

Metric Q1'26 Q4'25 Q3'25 Q2'25 Q1'25 Q4'24 Q3'24 Q2'24
Operating Cash Flow -$1.1M-80.4% -$601K+21.0% -$761K-30.4% -$584K+54.6% -$1.3M-66.6% -$771K-7.1% -$720K-23.6% -$583K
Capital Expenditures N/A N/A N/A N/A N/A N/A N/A N/A
Free Cash Flow N/A N/A N/A N/A N/A N/A N/A N/A
Investing Cash Flow N/A N/A N/A N/A N/A N/A N/A N/A
Financing Cash Flow N/A N/A N/A N/A N/A N/A N/A N/A
Dividends Paid N/A N/A N/A N/A N/A N/A N/A N/A
Share Buybacks N/A N/A N/A N/A N/A N/A N/A N/A

INTI Financial Ratios

Metric Q1'26 Q4'25 Q3'25 Q2'25 Q1'25 Q4'24 Q3'24 Q2'24
Gross Margin N/A N/A N/A N/A N/A N/A N/A N/A
Operating Margin N/A N/A N/A N/A N/A N/A N/A N/A
Net Margin N/A N/A N/A N/A N/A N/A N/A N/A
Return on Equity N/A N/A -20625.1%-20532.9pp -92.2%-45.4pp -46.8% N/A -21.5%-9.3pp -12.1%
Return on Assets -47.9% N/A -22.7%-5.8pp -16.9%-2.8pp -14.1% N/A -11.3%-4.3pp -7.0%
Current Ratio 3.60+0.4 3.19-31.8 35.00+7.6 27.36-19.3 46.68+38.7 8.03-136.8 144.78-57.1 201.91
Debt-to-Equity N/A N/A 12.79+12.7 0.07+0.0 0.04-1.8 1.87+1.0 0.89+0.2 0.73
FCF Margin N/A N/A N/A N/A N/A N/A N/A N/A

Note: Shareholder equity is negative (-$1.3M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Similar Companies

Pharmala Biotech MDXXF
$12.0M
Bioxytran Inc BIXT
$2.6M
Betterlife Pharma Inc BETRF
$26.8M
ZEO ScientifiX ZEOX
$12.9M
Genflow Biosciences GENFF
$22.7M

Frequently Asked Questions

No, Inhibitor Therap (INTI) reported a net income of -$3.3M in fiscal year 2025.

Inhibitor Therap (INTI) reported diluted earnings per share of $-0.02 for fiscal year 2025. This represents a 0.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

As of fiscal year 2025, Inhibitor Therap (INTI) had $2.4M in cash and equivalents against $37K in long-term debt.

Inhibitor Therap (INTI) generated -$3.2M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

Inhibitor Therap (INTI) had $2.5M in total assets as of fiscal year 2025, including both current and long-term assets.

Inhibitor Therap (INTI) invested $1.7M in research and development during fiscal year 2025.

Inhibitor Therap (INTI) had 173M shares outstanding as of fiscal year 2025.

Inhibitor Therap (INTI) had a current ratio of 3.19 as of fiscal year 2025, which is generally considered healthy.

Inhibitor Therap (INTI) had a return on assets of -131.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Based on fiscal year 2025 data, Inhibitor Therap (INTI) had $2.4M in cash against an annual operating cash burn of $3.2M. This gives an estimated cash runway of approximately 9 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Inhibitor Therap (INTI) has negative shareholder equity of -$1.3M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

Inhibitor Therap (INTI) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Inhibitor Therap (INTI) has an earnings quality ratio of 0.98x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Back to top